JHSM
Journal of Health Sciences and Medicine

Journal of Health Sciences and Medicine (JHSM) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

ISSN: Active
eISSN: 2636-8579
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Variant analysis of MiRNA regulatory genes in colorectal cancer
Abstract
Aims: The aim of this study was to investigate the clinical significance of mutations in AGO2, DICER and DROSHA genes, which are involved in miRNA biogenesis, as well as TP53, KRAS, BRAF, PI3KCA and APC genes, which are important in the pathophysiology of CRC, and their association with metastasis in patients diagnosed with sporadic colorectal cancer.
Methods: DNA isolation was performed by taking 10-micron sections from paraffin-embedded tissue samples of 12 patients diagnosed with CRC and Kapa NGS DNA extraction kit was used for sequence analysis. The purity and concentration of the DNA obtained was measured by Qubit fluoremeter, and NadPrep DNA Universal Library Preparation Kit was used for high quality library preparation. Bioinformatics analyses were performed on the Genomize Seq platform.
Results: In our study, metastasis was detected in 42% of 12 colorectal cancer patients. Mutations in at least two miRNA biogenesis genes were detected in 80% of metastatic patients. In addition, variants detected in miRNA biogenesis regulatory genes and oncogenic genes were summarized according to pathogenicity status according to the American College of Medical Genetics and Genomics (ACMG) classification.
Conclusion: Genes involved in miRNA biogenesis and mutations of clinically relevant genes in CRC have important implications on disease prognosis and response to therapy. Mutations in these genes may be associated with the development of metastases and mechanisms of resistance to treatment and may be potential genetic markers for the development of personalized treatment strategies.

Keywords : Colorectal cancer, miRNA biogenesis, AGO2, DICER, DROSHA

Download Article


1. Sager R. Expression genetics in cancer: shifting the focus fromDNA to RNA. Proc Natl Acad Sci USA. 1997;94(3):952-955.doi:10.1073/pnas.94.3.952
2. You JS, Jones PA. Cancer genetics and epigenetics: two sidesof the same coin? Cancer Cell. 2012;22(1):9-20. doi:10.1016/j.ccr.2012.06.008
3. Shen H, Laird PW. Interplay between the cancer genome andepigenome. Cell. 2013;153(1):38-55. doi:10.1016/j.cell.2013.03.008
4. Ganju A, Khan S, Hafeez BB, et al. miRNA nanotherapeutics forcancer. Drug Discov Today. 2017;22(2):424-432. doi:10.1016/j.drudis.2016.10.014
5. Krol J, Loedige I, Filipowicz W. The widespread regulationof microRNA biogenesis, function and decay. Nat Rev Genet.2010;11(9):597-610. doi:10.1038/nrg2843
6. Finnegan EF, Pasquinelli AE. MicroRNA biogenesis: regulatingthe regulators. Crit Rev Biochem Mol Biol. 2013;48(1):51-68. doi:10.3109/10409238.2012.738643
7. Wu K, He J, Pu W, Peng Y. The role of exportin-5 in microRNAbiogenesis and cancer. Genomics Proteomics Bioinformatics.2018;16(2):120-126. doi:10.1016/j.gpb.2017.09.004
8. Shomron N, Levy C. MicroRNA-biogenesis and pre-mRNAsplicing crosstalk. J Biomed Biotechnol. 2009;2009:594678.doi:10.1155/2009/594678
9. Bartel DP. MicroRNAs: target recognition and regulatory functions.Cell. 2009;136(2):215-233. doi:10.1016/j.cell.2009.01.002
10. Di Leva G, Garofalo M, Croce CM. MicroRNAs in cancer. AnnuRev Pathol. 2014;9(1):287-314. doi:10.1146/annurev-pathol-012513-104715
11. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, JemalA, Bray F. Global patterns and trends in colorectal cancerincidence and mortality. Gut. 2017;66(4):683-691. doi:10.1136/gutjnl-2015-310912
12. Mármol I, Sánchez-de-Diego C, Pradilla Dieste A, Cerrada E,Rodriguez Yoldi MJ. Colorectal carcinoma: a general overviewand future perspectives in colorectal cancer. Int J Mol Sci.2017;18(1):197 doi:10.3390/ijms18010197
13. Fleming M, Ravula S, Tatishchev SF, Wang HL. Colorectalcarcinoma: pathologic aspects. J Gastrointest Oncol. 2012;3(3):153-173. doi:10.3978/j.issn.2078-6891.2012.030
14. Tate JG, Bamford S, Jubb HC, et al. COSMIC: the catalogueof somatic mutations in cancer. Nucleic Acids Res.2018;47(D1):D941-D947. doi:10.1093/nar/gky1015
15. Zhu G, Pei L, Xia H, Tang Q, Bi F. Role of oncogenic KRAS inthe prognosis, diagnosis and treatment of colorectal cancer. MolCancer. 2021;20(1):143. doi:10.1186/s12943-021-01441-4
16. Gutierrez A, Demond H, Brebi P, Ili CG. Novel methylationbiomarkers for colorectal cancer prognosis. Biomolecules.2021;11(11):1722. doi:10.3390/biom11111722
17. Jung G, Hernández-Illán E, Moreira L, Balaguer F, Goel A.Epigenetics of colorectal cancer: biomarker and therapeuticpotential. Nat Rev Gastroenterol Hepatol. 2020;17(2):111-130.doi:10.1038/s41575-019-0230-y
18. Tanoglu A, Balta AZ, Berber U, et al. MicroRNA expressionprofile in patients with stage II colorectal cancer: a Turkishreferral center study. Asian Pac J Cancer Prev. 2015;16(5):1851-1855. doi:10.7314/apjcp.2015.16.5.1851
19. Muhammad S, Kaur K, Huang R, et al. MicroRNAs in colorectalcancer: role in metastasis and clinical perspectives. World JGastroenterol. 2014;20(45):17011-17019. doi:10.3748/wjg.v20.i45.17011
20. Jenike AE, Halushka MK. miR-21: a non-specific biomarker ofall maladies. Biomark Res. 2021;9(1):18. doi:10.1186/s40364-021-00272-1
21. He L, He X, Lim LP, et al. A microRNA component of the p53tumour suppressor network. Nature. 2007;447(7148):1130-1134.doi:10.1038/nature05939
22. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with arole in cancer. Nat Rev Cancer. 2006;6(4):259-269. doi:10.1038/nrc1840
23. Bandara KV, Michael MZ, Gleadle JM. MicroRNA biogenesis inhypoxia. Microrna. 2017;6(2):80-96. doi:10.2174/2211536606666170313114821
24. Ahluwalia P, Kolhe R, Gahlay GK. The clinical relevance ofgene expression based prognostic signatures in colorectalcancer. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188513.doi:10.1016/j.bbcan.2021.188513
25. Sun L, Fang Y, Wang X, et al. miR-302a inhibits metastasis andcetuximab resistance in colorectal cancer by targeting NFIBand CD44. Theranostics. 2019;9(26):8409-8425. doi:10.7150/thno.36605
26. Su R, Wu X, Tao L, Wang C. The role of epigenetic modifications incolorectal cancer metastasis. Clin Exp Metastasis. 2022;39(4):521-539. doi:10.1007/s10585-022-10163-w
27. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastaticcolorectal cancer: ESMO Clinical Practice Guidelines fordiagnosis, treatment and follow-up. Ann Oncol. 2014;25(Suppl3):iii1-iii9. doi:10.1093/annonc/mdu260
28. Hong Y, Liang H, Uzair ur R, et al. miR-96 promotes cellproliferation, migration and invasion by targeting PTPN9 in breastcancer. Scientif Rep. 2016;6(1):37421. doi:10.1038/srep37421
29. Yu S, Lu Z, Liu C, et al. miRNA-96 suppresses KRAS and functionsas a tumor suppressor gene in pancreatic cancer. Cancer Res.2010;70(14):6015-6025. doi:10.1158/0008-5472.Can-09-4531
30. Chen X, Guo X, Zhang H, et al. Role of miR-143 targeting KRASin colorectal tumorigenesis. Oncogene. 2009;28(10):1385-1392.doi:10.1038/onc.2008.474
31. Lin S, Gregory RI. MicroRNA biogenesis pathways in cancer. NatRev Cancer. 2015;15(6):321-333. doi:10.1038/nrc3932
32. Szczyrek M, Grenda A, Kuznar-Kaminska B, et al. Methylationof DROSHA and DICER as a biomarker for the detection of lungcancer. Cancers. 2021;13(23):6139. doi:10.3390/cancers13236139
33. Sung H, Jeon S, Lee KM, et al. Common genetic polymorphisms ofmicroRNA biogenesis pathway genes and breast cancer survival.BMC Cancer. 2012;12:195. doi:10.1186/1471-2407-12-195
34. Galka-Marciniak P, Urbanek-Trzeciak MO, Nawrocka PM, etal. Somatic mutations in miRNA genes in lung cancer-potentialfunctional consequences of non-coding sequence variants.Cancers. 2019;11(6):793. doi:10.3390/cancers11060793
35. Chen HY, Wang ML, Laurent B, et al. Musashi-1 promotes stress-induced tumor progression through recruitment of AGO2.Theranostics. 2020;10(1):201-217. doi:10.7150/thno.35895
36. Ke HL, Chen M, Ye Y, et al. Genetic variations in micro-RNA biogenesis genes and clinical outcomes in non-muscle-invasive bladder cancer. Carcinogenesis. 2013;34(5):1006-1011.doi:10.1093/carcin/bgt006
37. Rakheja D, Chen KS, Liu Y, et al. Somatic mutations in DROSHAand DICER1 impair microRNA biogenesis through distinctmechanisms in Wilms tumours. Nat Commun. 2014;2:4802.doi:10.1038/ncomms5802
38. Boni V, Zarate R, Villa JC, et al. Role of primary miRNApolymorphic variants in metastatic colon cancer patientstreated with 5-fluorouracil and irinotecan. Pharmacogenomics J.2011;11(6):429-436. doi:10.1038/tpj.2010.58
39. Testa U, Pelosi E, Castelli G. Colorectal cancer: geneticabnormalities, tumor progression, tumor heterogeneity, clonalevolution and tumor-initiating cells. Med Sci. 2018;6(2):31. doi:10.3390/medsci6020031
Article available in :
Volume 7, Issue 1, 2024
Page : 98-104
https://doi.org/10.32322/jhsm.1403868
Article Information
Received : 12 Ara 2023
Accepted : 30 Ara 2023
Published : 15 Oca 2024
Corresponding Author :

Özkan Bağcı: Department of Medical Genetics, Faculty of Medicine, Selçuk University, Konya, Turkiye

[email protected]
Citation : Bağcı Ö, Marzioğlu Özdemir E, Şanlıtürk B. Variant analysis of MiRNA regulatory genes in colorectal cancer. J Health Sci Med. 2024;7(1):98-104.

Read: 36
Cited: 0
Download : 32
_Footer